<DOC>
	<DOCNO>NCT01556438</DOCNO>
	<brief_summary>The purpose study evaluate safety effect body LY2127399 combination bortezomib dexamethasone Japanese patient relapse refractory multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Study LY2127399 Japanese Participants With Relapsed Refactory Multiple Myeloma</brief_title>
	<detailed_description>The study 3 cohort . Participants enroll one cohort . Cohort 2 cohort 2-SC conduct parallel . Cohort 1 - Participants receive 100 mg LY2127399 intravenously ( IV ) , 1.3 milligram per square meter ( mg/m^2 ) bortezomib IV , 20 mg dexamethasone orally . Cohort 2 - Participants receive 300 mg LY2127399 IV , 1.3 mg/m^2 bortezomib IV , 20 mg dexamethasone orally . Cohort 2-SC - Participants receive 300 mg LY2127399 IV , 1.3 mg/m^2 bortezomib subcutaneously ( SC ) , 20 mg dexamethasone orally . Cohort 2-SC add per protocol amendment February 2013 .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have relapse refractory MM treat least 1 prior regimen . Prior therapy bortezomib allow previously least minimal response ( MR ) . Have measurable disease define one following : serum Mprotein concentration ≥ 1 g/dL ( 10 g/L ) urine monoclonal light chain concentration ≥ 200 mg/24 hour determine urine protein electrophoresis involve serum free light chain ( SFLC ) concentration ≥ 10 mg/dL ( 100 mg/L ) abnormal SFLC ratio Have adequate organ function include : Absolute neutrophil count ( ANC ) ≥ 1000/microliter Platelet ( PLT ) count ≥ 75,000/microliter Hemoglobin ( Hgb ) ≥ 8.0 g/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ( total elevate check direct , normal , patient eligible ) Aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN Serum creatinine ≤ 3.0 mg/dL . Have Eastern Cooperative Oncology Group performance status ( ECOG PS ) score ≤ 2 . Have discontinue previous therapy cancer , include chemotherapy , surgery , radiotherapy least 2 week ( 6 week mitomycinC nitrosoureas ) study enrollment recover acute effect therapy . Males female reproductive potential : Must agree use medically approve contraceptive precaution study 4 month follow last dose study drug . Females childbearing potential : Must negative urine serum pregnancy test &lt; 7 day first dose study drug . Have estimate life expectancy ≥16 week , opinion investigator . Have receive treatment within 30 day initial dose study drug experimental agent noncancer indication receive regulatory approval indication . Have one serious preexist medical condition , opinion investigator , would preclude participation study . Have uncontrolled infection . Females pregnant breastfeeding . Have know positive test result human immunodeficiency virus ( HIV ) , hepatitis B* , hepatitis C antibody ( HCAb ) . * Have evidence test positive hepatitis B . A positive test hepatitis B define : 1. positive hepatitis B surface antigen ( HBsAg+ ) . OR 2. positive antihepatitis B core antibody positive hepatitis B deoxyribonucleic acid ( HBV DNA ) . OR 3. positive antihepatitis B surface antibody ( HBsAb+ ) positive hepatitis B deoxyribonucleic acid ( HBV DNA ) . Have ≥ Grade 2 peripheral neuropathy grade pain assess use Common Terminology Criteria Adverse Events , version 4.03 ( CTCAE v 4.03 ) . Have previously receive allogenic hematopoietic stem cell transplant . Have previously receive treatment experimental agent target Bcell activate factor ( BAFF ) . Have correct QT ( QTc ) interval &gt; 470 msec baseline electrocardiogram ( ECG ) . Have interstitial pneumonitis ( interstitial pneumonia ) pulmonary fibrosis manifest opacity chest Xray compute tomography ( CT ) scan . Have another active malignancy within past 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>